Uncover key drivers, emerging technologies, and competitive movements shaping the neoantigen targeted therapies market from 2026–2035 with trusted insights from The Business Research Company
How much larger will the Neoantigen Targeted Therapies Market be in 2030 compared with 2026?
The market size for neoantigen targeted therapies has witnessed rapid expansion over recent years. It is anticipated to increase from $4.71 billion in 2025 to $6.39 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 35.8%. The historical growth in this sector is attributable to various factors including limited immunotherapy options, the slow progress in cancer vaccine development, the initial stages of genomic sequencing usage, restricted access to clinical trials, and a continued dependence on traditional oncology treatments.
The neoantigen targeted therapies market is projected to experience significant expansion in the coming years. This market is forecast to reach $21.52 billion by 2030, demonstrating a robust compound annual growth rate (CAGR) of 35.5%. The projected growth is primarily driven by the rapid advancement of personalized cancer therapies, increased investment in genomic sequencing, the expansion of clinical research collaborations, a rising adoption of combination immunotherapies, and a growing demand for precision oncology solutions. Noteworthy trends during this forecast period include the increasing uptake of personalized cancer vaccines, an expansion of targeted immunotherapy research pipelines, a rise in clinical trials for neoantigen-based combination therapies, the growing demand for early genetic profiling in oncology, and a surge in the development of TIL-based therapeutic approaches.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11944&type=smp
What Drivers Are Guiding Growth Patterns In The Neoantigen Targeted Therapies Market?
The increasing prevalence of precision oncology is projected to stimulate the expansion of the neoantigen targeted therapies market moving forward. Precision oncology is a cancer treatment approach that employs detailed genetic and molecular data from a patient’s tumor to direct the selection of targeted therapies. This method integrates neoantigen-targeted therapies by utilizing advanced genomic analysis to identify distinct neoantigens expressed by an individual’s cancer cells. The application of neoantigen-targeted therapies within precision oncology represents a strategy to address the specific genetic makeup of each patient’s tumor, offering a more tailored and effective treatment option. For example, in March 2024, information from the Precision Oncology Clinical Trials & Statistics 2024 report, published by Novotech, an Australia-based full-service clinical contract research organization involved in developing innovative therapeutics, revealed that by November 2023, twelve treatments had obtained FDA approval for specific biomarker-selected indications, with six of these also incorporated into the NCCN guidelines. By the close of the year, 43% of the 217 FDA-approved oncology therapies were designated as precision oncology, and 78 of these therapies incorporated DNA or NGS-detectable biomarkers, emphasizing the growing significance of biomarker-guided treatments in cancer care. Thus, the growth in precision oncology is propelling the expansion of the neoantigen targeted therapies market.
How Is The Neoantigen Targeted Therapies Market Divided Into Segments?
The neoantigen targeted therapies market covered in this report is segmented –
1) By Type: Monotherapy, Combination Therapy
2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies
3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer
4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous
5) By Application: Medical Research Institution, Hospitals and Clinics, Other Applications
Subsegments:
1) By Monotherapy: Individual Neoantigen-Targeted Treatments
2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies, Neoantigen-Targeted Therapies Combined With Chemotherapy, Neoantigen-Targeted Therapies Combined With Targeted Therapies
Which Trends Are Influencing The Performance And Direction Of The Neoantigen Targeted Therapies Market?
Leading firms within the neoantigen targeted therapies market are employing a strategic partnership strategy to customize neoantigen vaccines and monoclonal antibody medications, aiming to address the difficulties posed by current immunotherapy for solid tumor treatment. These alliances involve businesses utilizing each other’s strengths and assets to attain shared advantages and successful outcomes. As an illustration, in April 2023, Moderna, Inc., a pharmaceutical and biotechnology firm from the US, joined forces with Merck & Co., Inc., another US pharmaceutical company, to introduce mRNA-4157 (V940). This experimental individualized neoantigen therapy (INT) is engineered to elicit a specific anti-tumor immune response corresponding to the distinct mutational profile of a patient’s tumor. mRNA-4157 (V940) functions by encoding as many as 34 neoantigens to stimulate T cell reactions, thereby boosting the body’s capacity to identify and eliminate tumor cells when administered alongside Merck’s immunotherapy KEYTRUDA. The objective of this combined treatment is to enhance recurrence-free survival for individuals with high-risk resected melanoma.
Which Major Industry Participants Are Leading The Neoantigen Targeted Therapies Market Growth?
Major companies operating in the neoantigen targeted therapies market are F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, Kite Pharma Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report
Which Geographic Areas Are Emerging As Strong Markets For The Neoantigen Targeted Therapies Market?
North America was the largest region in the neoantigen targeted therapies market in 2025. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Neoantigen Targeted Therapies Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=11944&type=smp
Browse Through More Reports Similar to the Global Neoantigen Targeted Therapies Market 2026, By The Business Research Company
Leukemia Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report
Targeted Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report
Anti Neoplastic Agents Market Report 2026
https://www.thebusinessresearchcompany.com/report/anti-neoplastic-agents-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model